Revolution Medicines Gains as New Buy Rating Adds to Recent Regulatory Momentum

Revolution Medicines (RVMD) is up 4.8% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely driver appears to be a fresh Buy initiation from Goldman Sachs, which gave investors another bullish read on Revolution Medicines’ oncology platform and pipeline. The move may also be getting support from the company’s recent FDA Breakthrough Therapy Designation for RASONQUE in first-line metastatic pancreatic cancer, which continues to reinforce the regulatory story.

Details:

Goldman Sachs initiated coverage of RVMD with a Buy rating on September 24, 2026, highlighting confidence in the company’s targeted cancer drug platform and commercial opportunity.

Earlier in September, Revolution Medicines announced that the FDA granted Breakthrough Therapy Designation to RASONQUE in combination with chemotherapy for first-line metastatic pancreatic cancer.

The company has been building momentum after the recent U.S. approval of RASONQUE, giving investors a transition story from clinical-stage biotech to commercial-stage oncology company.

This could also be because traders are continuing to reprice the stock after a series of positive regulatory and Wall Street developments over the past several weeks.

Sources:

Revolution Medicines, SEC, Investing.com

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$RVMD Insider Trading Activity

$RVMD insiders have traded $RVMD stock on the open market 96 times in the past 6 months. Of those trades, 0 have been purchases and 96 have been sales.

Here’s a breakdown of recent trading of $RVMD stock by insiders over the last 6 months:

MARK A GOLDSMITH (See Remarks) has made 0 purchases and 22 sales selling 230,008 shares for an estimated $40,352,843.
STEPHEN MICHAEL KELSEY (See Remarks) has made 0 purchases and 11 sales selling 102,275 shares for an estimated $20,486,119.
MARGARET A HORN (Chief Operating Officer) has made 0 purchases and 11 sales selling 104,967 shares for an estimated $16,883,735.
LORENCE H. KIM has made 0 purchases and 14 sales selling 73,090 shares for an estimated $14,967,124.
JEFF CISLINI (SVP & General Counsel) has made 0 purchases and 9 sales selling 62,417 shares for an estimated $12,911,626.
ANTHONY MANCINI (See Remarks) has made 0 purchases and 15 sales selling 29,842 shares for an estimated $5,468,887.
JACK ANDERS (Chief Financial Officer) has made 0 purchases and 3 sales selling 6,775 shares for an estimated $1,232,469.
SUSHIL PATEL has made 0 purchases and 9 sales selling 5,580 shares for an estimated $1,048,967.
ALAN B. SANDLER (Chief Development Officer) has made 0 purchases and 2 sales selling 341 shares for an estimated $67,940.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

EARLY ACCESS

Receive RVMD Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$RVMD Hedge Fund Activity

We have seen 471 institutional investors add shares of $RVMD stock to their portfolio, and 229 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

DARWIN GLOBAL MANAGEMENT, LTD. added 8,418,804 shares (+380.8%) to their portfolio in Q2 2026, for an estimated $1,576,673,613
ADAGE CAPITAL PARTNERS GP, L.L.C. removed 4,878,385 shares (-89.1%) from their portfolio in Q2 2026, for an estimated $913,623,942
CAPITAL WORLD INVESTORS added 4,008,244 shares (+inf%) to their portfolio in Q2 2026, for an estimated $750,663,936
FMR LLC added 3,736,108 shares (+44.1%) to their portfolio in Q2 2026, for an estimated $699,698,306
JPMORGAN CHASE & CO added 3,298,066 shares (+inf%) to their portfolio in Q2 2026, for an estimated $617,661,800
BLACKROCK, INC. added 2,483,084 shares (+22.1%) to their portfolio in Q2 2026, for an estimated $465,031,971
WELLINGTON MANAGEMENT GROUP LLP removed 2,184,404 shares (-36.2%) from their portfolio in Q2 2026, for an estimated $409,095,181

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$RVMD Price Targets

Multiple analysts have issued price targets for $RVMD recently. We have seen 14 analysts offer price targets for $RVMD in the last 6 months, with a median target of $195.0.

Here are some recent targets:

Michael Schmidt from Guggenheim set a target price of $235.0 on 07/09/2026
Robert Burns from HC Wainwright & Co. set a target price of $195.0 on 07/06/2026
Joseph Catanzaro from Mizuho set a target price of $215.0 on 07/06/2026
Robert Driscoll from Wedbush set a target price of $181.0 on 07/02/2026
Gregory Renza from Truist Securities set a target price of $210.0 on 06/30/2026
Ami Fadia from Needham set a target price of $235.0 on 06/29/2026
Cory Kasimov from Evercore ISI Group set a target price of $220.0 on 06/10/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.